Replies to post #139661 on Biotech Values

[DewDiligence]

Your take is on-target, IMO. Market cap* should be used as a reality check rather than a substitute for genuine DD. That’s why I suggested that #msg-73956933 should be required reading for PPHM longs, who have been proclaiming for about a decade that clinical greatness is just around the corner despite the stock’s minuscule enterprise value and the lack of interest from any partner or suitor.

*Enterprise value is a better metric than market cap for this purpose.

[Superfly15]

After looking more deeply at peri's clinical data, I didn't need AF's market cap rule to tell me that X-PECT's chance of succeeding wasn't going to be good (though I did think there would at least be an efficacious sub-group).

As did I. Again, I said it is something for NEW biotech investors to keep an eye on. Not everybody knows how to read in-depth pharma data when starting...myself included. 3 years going and I still have much to learn.